Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM2 | Q9P1W9 | 19/20 | 0.72 |
| ▸ | PIM1 | P11309 | 17/20 | 0.72 |
| ▸ | PIM3 | Q86V86 | 17/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | GSK3B | P49841 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12079359 | 0.92 | PIM2 (0.75) | PIM2PIM1PIM3CYP3A4CYP2D6 | |
| SCHEMBL12079922 | 0.88 | PIM2 (0.58) | PIM2PIM1PIM3CYP3A4CYP2D6 | |
| SCHEMBL12080175 | 0.87 | PIM2 (0.56) | PIM2PIM1PIM3CYP3A4CYP2D6 | |
| SCHEMBL12079637 | 0.87 | PIM1 (0.55) | PIM2PIM1PIM3 | |
| SCHEMBL12081185 | 0.85 | PIM2 (0.84) | PIM2PIM1PIM3 | |
| SCHEMBL12079490 | 0.85 | PIM2 (0.84) | PIM2PIM1PIM3 | |
| SCHEMBL12081159 | 0.85 | PIM3 (0.76) | PIM2PIM1PIM3CYP3A4CYP2D6 | |
| SCHEMBL16754173 | 0.85 | PIM1 (0.75) | PIM2PIM1PIM3 | |
| SCHEMBL2694153 | 0.84 | PIM1 (1.00) | PIM2PIM1PIM3 | |
| SCHEMBL2694159 | 0.84 | PIM1 (1.00) | PIM2PIM1PIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140228363-A1 | TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
| US-20140228363-A1 | TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
| US-20120225061-A1 | TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-09-06 | — | — | US | disclosed |
| US-20120225061-A1 | TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228363-A1 | TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS | PIM1, PIM2, PIM3 | PIM2 2/4885PIM1 1/4885PIM3 3/4885 |
| US-20120225061-A1 | TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS | PIM1, PIM2, PIM3 | PIM2 2/4885PIM1 1/4885PIM3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.